Pfizer to test Summit's white-hot bispecific with ADCs
Pfizer has teamed up with Summit Therapeutics to assess whether one of the industry’s hottest cancer candidates works well with its antibody-drug conjugates (ADCs). Miami-based Summit holds the rights to the PD-1xVEGF bispecific ivonescimab in territories including the U.
Summit Therapeutics established a clinical trial collaboration with Pfizer to develop ivonescimab for NSCLC and solid tumors.
The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially ...
Chinese scientists are celebrating a new breakthrough cancer drug, but some Chinese citizens are skeptical of domestically ...
Few companies in the biotech industry have performed better in the past two years than Summit Therapeutics (NASDAQ: SMMT).
But if not, you'll need to find stocks that hold the potential to pack more punch. The past doesn't predict the future, but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback